ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

ClinicalTrials.gov ID: NCT00924989

Public ClinicalTrials.gov record NCT00924989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Study identification

NCT ID
NCT00924989
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Astellas Pharma Inc
Industry
Enrollment
139 participants

Conditions and interventions

Interventions

  • OSI-906 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2009
Primary completion
Jul 10, 2012
Completion
Oct 7, 2012
Last update posted
Nov 19, 2024

2009 – 2012

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
TGen Clinical Research Service at Scottsdale Healthcare Scottsdale Arizona 85258
University of Southern California Los Angeles California 90033
UCLA Los Angeles California 90095
University of Colorado Denver Cancer Center Aurora Colorado 80045
University of Miami Miami Florida 33136
Dana-Farber Cancer Institute Boston Massachusetts 02115
University of Michigan Ann Arbor Michigan 48109-2200
Karmanos Cancer Institute Detroit Michigan 48201
Dartmouth Medical School Lebanon New Hampshire 03756
Duke Clinical Cancer Trials Services Durham North Carolina 27710
Ohio State University Columbus Ohio 43202
Vanderbilt University Medical Center Nashville Tennessee 37232-6307
Mary Crowley Cancer Research Center Dallas Texas 75230
MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00924989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00924989 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →